Successful treatment of pyoderma gangrenosum in a patient winh ulcerative colitis and COVID-19 infection: case report

Abstract

Pyoderma gangrenosum is a rare inflammatory neutrophilic dermatosis, which causes ulceration of the skin. The condition is commonly associated with underlying systemic disorders such as inflammatory bowel disease, arthritis, and hematological disorders. Herein, we describe the case of a familiar association between pyoderma gangrenosum and ulcerative colitis complicated by the newly COVID-19 infection.

It is of particular clinical interest to address pyoderma gangrenosum lesions with concurrent treatment of associated disorders that may have influence on the course of the ulcer. Moreover, the therapy should cover as many diseases as possible while not being excessive to minimize possible side effects.

Thus, the selection of treatment that spans mutual pathophysiological features of all comorbidities represents the best option to make when handling pyoderma gangrenosum patients.

We present a case of the development of gangrenous pyoderma against the background of ulcerative colitis complicated by the new coronavirus infection COVID-19, which will raise awareness of gangrenous pyoderma as a relatively rare cause of ulcerative necrotic skin lesions, which can easily be confused with an infectious process.

Of particular clinical importance in the conditions of the COVID-19 pandemic is the correct treatment of gangrenous pyoderma. Only an integrated approach can give a positive result from the therapy.

Keywords

pyoderma gangrenosum / ulcerative colitis / COVID-19 / case report

References

[1] Marzano AV, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176(6):1588–1598. doi: 10.1111/bjd.15226

[2] Marzano A.V., Damiani G., Ceccherini I., et al. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis) // Br J Dermatol. 2017. Vol. 176, N 6. Р. 1588–1598. doi: 10.1111/bjd.15226

[3] Alavi A, French LE, Davis MD, et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017;18(3):355–372. doi: 10.1007/s40257-017-0251-7

[4] Alavi A., French L.E., Davis M.D., et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment // Am J Clin Dermatol. 2017. Vol. 18, N 3. Р. 355–372. doi: 10.1007/s40257-017-0251-7

[5] Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(4):479–487. doi: 10.1007/s40257-018-0356-7

[6] Kridin K., Cohen A.D., Amber K.T. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis // Am J Clin Dermatol. 2018. Vol. 19, N 4. Р. 479–487. doi: 10.1007/s40257-018-0356-7

[7] Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790-800. doi: 10.1111/j.1365-4632.2004.02128.x

[8] Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria // Int J Dermatol. 2004. Vol. 43, N 11. P.790-800. doi: 10.1111/j.1365-4632.2004.02128.x

[9] Georgin-Lavialle S, Ducharme-Benard S, Sarrabay G, et al. Systemic autoinflammatory diseases: Clinical state of the art. Best Pract Res Clin Rheumatol. 2020;34(4):101529. doi: 10.1016/j.berh.2020.101529

[10] Georgin-Lavialle S., Ducharme-Benard S., Sarrabay G., et al. Systemic autoinflammatory diseases: clinical state of the art // Best Pract Res Clin Rheumatol. 2020. Vol. 34, N 4. Р. 101529. doi: 10.1016/j.berh.2020.101529

[11] Barbosa NS, Tolkachjov SN, El-Azhary RA, et al. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013. J Am Acad Dermatol. 2016;75(5):931–939. doi: 10.1016/j.jaad.2016.05.044

[12] Barbosa N.S., Tolkachjov S.N., El-Azhary R.A., et al. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013 // J Am Acad Dermatol. 2016. Vol. 75, N 5. Р. 931–939. doi: 10.1016/j.jaad.2016.05.044

[13] Ashchyan HJ, Butler DC, Nelson CA, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2018;154(4):409–413. doi: 10.1001/jamadermatol.2017.5978

[14] Ashchyan H.J., Butler D.C., Nelson C.A., et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum // JAMA Dermatol. 2018. Vol. 154, N 4. Р. 409–413. doi: 10.1001/jamadermatol.2017.5978

[15] Goodarzi H, Sivamani RK, Garcia MS, et al. Effective strategies for the management of pyoderma gangrenosum. Adv Wound Care (New Rochelle). 2012;1(5):194–199. doi: 10.1089/wound.2011.0339

[16] Goodarzi H., Sivamani R.K., Garcia M.S., et al. Effective strategies for the management of pyoderma gangrenosum // Adv Wound Care (New Rochelle). 2012. Vol. 1, N 5. Р. 194–199. doi: 10.1089/wound.2011.0339

[17] Teplyuk NP, Grabovskaya OV, Kusraeva DT, Varshavsky VA. Pyoderma gangrenosum: examination and treatment experience. Russian journal of skin and venereal diseases. 2022;25(1):61–72. (In Russ). doi: 10.17816/dv105685

[18] Теплюк Н.П., Грабовская О.В., Кусраева Д.Т., Варшавский В.А. Гангренозная пиодермия: опыт обследования и лечения // Российский журнал кожных и венерических болезней. 2022. Т. 25, № 1. C. 61–72. doi: 10.17816/dv105685

[19] Olisova OY, Anpilogova EM. New coronavirus infection (COVID-19): a dermatologist’s view. Annals of the Russian academy of medical sciences. 2020;75(4):292–299. (In Russ). doi: 10.15690/vramn1359

[20] Олисова О.Ю., Анпилогова Е.М. Новая коронавирусная инфекция (COVID-19): взгляд дерматолога // Вестник Российской академии медицинских наук. 2020. Т. 75, № 4. С. 292–299. doi: 10.15690/vramn1359

[21] Genovese G, Moltrasio C, Berti E, Marzano AV. Skin manifestations associated with COVID-19: current knowledge and future perspectives. Dermatology. 2021;237(1):1–12. doi: 10.1159/000512932

[22] Genovese G., Moltrasio C., Berti E., Marzano A.V. Skin manifestations associated with COVID-19: current knowledge and future perspectives // Dermatology. 2021. Vol. 237, N 1. Р. 1–12. doi: 10.1159/000512932

[23] Borges L, Pithon-Curi TC, Curi R, Hatanaka E. COVID-19 and neutrophils: the relationship between hyperinflammation and neutrophil extracellular traps. Mediators Inflamm. 2020;2020:8829674. doi: 10.1155/2020/8829674

[24] Borges L., Pithon-Curi T.C., Curi R., Hatanaka E. COVID-19 and neutrophils: the relationship between hyperinflammation and neutrophil extracellular traps // Mediators Inflamm. 2020. Vol. 2020. Р. 8829674. doi: 10.1155/2020/8829674

[25] Patel F, Fitzmaurice S, Duong C, et al. Effective strategies for the management of pyoderma gangrenosum: A comprehensive review. Acta Derm Venerol. 2015;95(5):525–531. doi: 10.2340/00015555-2008

[26] Patel F., Fitzmaurice S., Duong C., et al. Effective strategies or the management of pyoderma gangrenosum: a comprehensive review // Acta Derm Venerol. 2015. Vol. 95, N 5. Р. 525–531. doi: 10.2340/00015555-2008

[27] Soto Vilches F, Vera-Kellet C. Pyoderma gangrenosum: classic and emerging therapies. Medicina Clínica (English Edition). 2017;149(6):256–260. doi: 10.1016/j.medcle.2017.08.007

[28] Soto Vilches F., Vera-Kellet C. Pyoderma gangrenosum: classic and emerging therapies // Medicina Clínica (English Edition). 2017. Vol. 149, N 6. Р. 256–260. doi: 10.1016/j.medcle.2017.08.007

[29] Schwartz RA, Pradhan S, Murrell DF, et al. COVID-19 and immunosuppressive therapy in dermatology. Dermatologic Therapy. 2020;33(6):e14140. doi: 10.1111/dth.14140

[30] Schwartz R.A., Pradhan S., Murrell D.F., et al. COVID-19 and immunosuppressive therapy in dermatology // Dermatologic Therapy. 2020. Vol. 33, N 6. Р. e14140. doi: 10.1111/dth.14140

[31] Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol. 2018;30(1):1–10. doi: 10.1515/jbcpp-2018-0036

[32] Tatiya-Aphiradee N., Chatuphonprasert W., Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis // J Basic Clin Physiol Pharmacol. 2018. Vol. 30, N 1. Р. 1–10. doi: 10.1515/jbcpp-2018-0036

[33] Syed K, Chaudhary H, Balu B. Pyoderma gangrenosum following COVID-19 infection. J Community Hosp Intern Med Perspect. 2021;11(5):601–603. doi: 10.1080/20009666.2021.1958492

[34] Syed K., Chaudhary H., Balu B. Pyoderma gangrenosum following COVID-19 infection // J Community Hosp Intern Med Perspect. 2021. Vol. 11, N 5. Р. 601–603. doi: 10.1080/20009666.2021.1958492

[35] Kochar B, Herfarth N, Mamie C, et al. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17(5):991–993. doi: 10.1016/j.cgh.2018.10.047

[36] Kochar B., Herfarth N., Mamie C., et al. Tofacitinib for the treatment of pyoderma gangrenosum // Clin Gastroenterol Hepatol. 2019. Vol. 17, N 5. Р. 991–993. doi: 10.1016/j.cgh.2018.10.047

[37] Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132–1138. doi: 10.1136/annrheumdis-2020-217927

[38] Fauny M., Moulin D., D’Amico F., et al. Paradoxical gastrointestinal effects of interleukin-17 blockers // Ann Rheum Dis. 2020. Vol. 79, N 9. Р. 1132–1138. doi: 10.1136/annrheumdis-2020-217927

[39] Mikail M, Wilson A. Infliximab treatment for large, multifocal, abdominal pyoderma gangrenosum associated with ulcerative colitis: a case report. SAGE Open Med Case Rep. 2020;8:2050313X20964113. doi: 10.1177/2050313X20964113

[40] Mikail M., Wilson A. Infliximab treatment for large, multifocal, abdominal pyoderma gangrenosum associated with ulcerative colitis: a case report // SAGE Open Med Case Rep. 2020. Vol. 8. Р. 2050313X20964113. doi: 10.1177/2050313X20964113

[41] Kleinpenning MM, Langewouters AM, van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22(5):261–265. doi: 10.3109/09546631003797106

[42] Kleinpenning M.M., Langewouters A.M., Van De Kerkhof P.C., Greebe R.J. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab // J Dermatolog Treat. 2011. Vol. 22, N 5. Р. 261–265. doi: 10.3109/09546631003797106

[43] Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203–1205. doi: 10.1001/archdermatol.2011.168

[44] Guenova E., Teske A., Fehrenbacher B., et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab // Arch Dermatol. 2011. Vol. 147, N 10. Р. 1203–1205. doi: 10.1001/archdermatol.2011.168

[45] Pichler M, Thuile T, Gatscher B, et al. Systematic review of surgical treatment of pyoderma gangrenosum with negative pressure wound therapy or skin grafting. J Eur Acad Dermatol Venereol. 2017;31(2):e61–e67. doi: 10.1111/jdv.13727

[46] Pichler M., Thuile T., Gatscher B., et al. Systematic review of surgical treatment of pyoderma gangrenosum with negative pressure wound therapy or skin grafting // J Eur Acad Dermatol Venereol. 2017. Vol. 31, N 2. Р. e61–e67. doi: 10.1111/jdv.13727

RIGHTS & PERMISSIONS

Teplyuk N.P., Grabovskaya O.V., Kusraeva D.T., Grekova E.V., Koriakin D.A., Kostenko A.Y.